MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
CareDx, Inc Cost of Revenue 2011-2026 | CDNA
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue CareDx, Inc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 45.5 M | 33 M | 21.4 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.5 M | 21.4 M | 33.3 M |
Quarterly Cost of Revenue CareDx, Inc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15 M | 12.4 M | - | 11.5 M | 11.5 M | 9.73 M | - | 8.89 M | 7.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15 M | 7.21 M | 10.9 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
6.6 M | $ 19.0 | 0.11 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 20.8 | 0.85 % | $ 226 M |  China |
 |
Co-Diagnostics
CODX
|
4.18 M | $ 0.17 | -5.26 % | $ 4.99 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 39.06 | -0.64 % | $ 1.08 B | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
9.67 B | $ 229.23 | -0.65 % | $ 168 B | USA |
 |
DarioHealth Corp.
DRIO
|
14.4 M | $ 10.98 | 2.62 % | $ 312 M | Israel |
 |
BioNano Genomics
BNGO
|
30.4 M | $ 1.52 | 1.2 % | $ 1.93 M | USA |
 |
Exact Sciences Corporation
EXAS
|
221 M | $ 101.86 | -0.04 % | $ 18.9 B | USA |
 |
DexCom
DXCM
|
1.33 B | $ 66.52 | -0.81 % | $ 25.7 B | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 26.19 | -1.13 % | $ 792 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
10 B | $ 225.57 | -0.92 % | $ 40.9 B | USA |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
NeoGenomics
NEO
|
370 M | $ 11.82 | -3.35 % | $ 1.5 B | USA |
 |
Myriad Genetics
MYGN
|
252 M | $ 6.12 | -0.89 % | $ 554 M | USA |
 |
ENDRA Life Sciences
NDRA
|
173 K | $ 4.45 | -6.62 % | $ 2.39 M | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 7.03 | -0.35 % | $ 1.52 B | USA |
 |
Illumina
ILMN
|
1.51 B | $ 130.74 | -1.51 % | $ 20.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 27.17 | -0.79 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
57.8 M | $ 7.96 | -0.13 % | $ 472 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
6.63 B | $ 173.69 | -1.03 % | $ 19.3 B | USA |
 |
RadNet
RDNT
|
1 B | $ 70.92 | -0.8 % | $ 5.18 B | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
9.38 B | $ 251.26 | -0.72 % | $ 21.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 181.71 | -0.7 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.52 B | $ 676.07 | -0.92 % | $ 55.8 B | USA |
 |
Lantheus Holdings
LNTH
|
546 M | $ 66.81 | -0.52 % | $ 4.62 B | USA |